Father of 4 delightful daughters, musician, computer scientist, people lover, avid cyclist, and all the while enjoying life with a Peter Pan mentality.
Snohomish, WA
Joined February 2021
- Tweets598
- Following111
- Followers244
- Likes2.1K
Perfectspike Auto Trendlines 2026 - #NVDA #TradingView
tradingview.com/script/pHdQi…
I've programmed an indicator in pine script (TradingView) that draws short-term and long-term angled trend lines from confirmed swing pivots, and overlays a horizontal SR matching system.
Ken Green retweeted
$RGBP $RGBPP
Regen presenting at Emerging Growth Conference January 25, 2023
otcmarkets.com/stock/RGBP/ne…
Ken Green retweeted
$RGBP $RGBPP
Link to Regen presentation at Emerging Growth Conference archived
youtube.com/watch?v=kRcn1R34…
$RGBP $RGBPP Dec. 8 2022: Regen Biopharma referenced in dendritic and tumor cell cancer vaccines market growth report.
“Dendritic cell-based anti-tumor vaccines have great potential for the treatment of cancer”.
Read more: tinyurl.com/u7wyym6a
$RGBP $RGBPP Dec. 2 2022: Cell therapy market report calls out Regen Biopharma as a key player, where live T-cells are injected into a patient for the treatment of cancer and other disorders.
Read more: tinyurl.com/2p96f57p
Ken Green retweeted
$RGBP Live Emerging Growth Conference on 11/30
@TheRegenBio @RegenBioPharm
Register:
goto.webcasts.com/starthere.…
Questions for the Company?
[email protected]
To Present
[email protected]
305-330-1985
Invites:
$COSM $NUWE $TCDA $CFRX $JAGX $OTTC $ZOM $TENX
$RGBP $RGBPP News today Nov. 18. ProMab Biotechnologies, Inc. was contracted in Sept. 2022 to validate Regen’s shRNA NR2F6-inhibiting technology. Today Regen announced first in vitro experiments designed to accomplish this validation was successful.
prnewswire.com/news-releases…
Ken Green retweeted
Regen BioPharma is presenting at Emerging Growth Conference $RGBP $RGBPP
finance.yahoo.com/news/regen…
Regen's patent pending proprietary intellectual property may address issues of both tumor microenvironment and cell exhaustion, allowing CAR-T to act as an effective therapy for solid tumors as well as blood cancers. Aptly named #DuraCAR (durable) CAR-T therapy. $RGBP $RGBPP
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. $RGBP $RGBPP #DuraCAR
tinyurl.com/4rd7mru4
👉 "In a future press release, the Company will describe its proprietary CAR-T drug, DuraCAR." $RGBP $RGBPP
prnewswire.com/news-releases…
$RGBP $RGBPP Oct. 26: In a press release today Regen reveals the name of its new CAR-T drug (DuraCAR). Dr. Koos believes that this drug can be an effective therapy for solid tumors as well as blood cancers using patented technology.
prnewswire.com/news-releases…
$RGBP $RGBPP Oct. 26: In a press release today Regen reveals the name of its new CAR-T drug (DuraCAR). Dr. Koos believes that this drug can be an effective therapy for solid tumors as well as blood cancers using patented technology.
prnewswire.com/news-releases…
This patent application discloses novel means of generating CAR-T cells which upon activation stimulate production of various T cell-specific compounds... which act as molecular beacons that call in all surrounding T cells and instruct them to kill the cancer cell. $RGBP $RGBPP
This quoted post is unavailable.
$RGBP
Regen prev. was issued US patent #11,090,332 (Means of generating T cell immune responses to the solid tumor antigen survivin) as well as US Patent # 11,141,471 covering NR2F6 silenced CAR-T, and plans to combine these technologies with those in a patent filed 10-5-22.
This quoted post is unavailable.
$RGBP $RGBPP New patent filed Sept. 19.
Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach
"...the first combination of an immunotherapy and a gene silencing agent in a single drug."
prnewswire.com/news-releases…